FDA Approves Absorica LD (isotretinoin) for Severe Recalcitrant Nodular Acne
FDA approves new acne drug Absorica LD for severe nodular acne.
FDA approved Absorica LD (isotretinoin) for severe recalcitrant nodular acne in non-pregnant patients aged 12 and older. It is reserved for …
The FDA approved Absorica LD (isotretinoin) for severe nodular acne in patients 12 and older. It is for those who have not improved with oth…
FDA Approves Absorica (isotretinoin) for Severe Recalcitrant Nodular Acne
FDA approves new acne drug Absorica for severe cases
The FDA approved Absorica (isotretinoin) for severe recalcitrant nodular acne in non-pregnant patients 12 years and older. It is reserved fo…
The FDA approved Absorica (isotretinoin) for severe nodular acne in patients 12 and older. It is for those who have not improved with other …
Nemolizumab Q4W improves IGA success maintenance by 11.8% over withdrawal in atopic dermatitis
Trial shows nemolizumab maintains skin results for atopic dermatitis
This Phase 3 randomized controlled trial evaluated nemolizumab in 507 adolescents and adults with moderate-to-severe atopic dermatitis who w…
A new trial found that nemolizumab helps maintain clear skin and reduce itching for adults and teens with moderate to severe atopic dermatit…
SSGJ-608 achieves 92.7% to 95.1% PASI75 response in moderate-to-severe plaque psoriasis
New injection shows promise for moderate to severe plaque psoriasis
This phase 3 randomized trial in 770 patients with moderate-to-severe plaque psoriasis found that SSGJ-608 (80mg every 2 weeks or 160mg ever…
A new injectable treatment showed high success rates in clearing skin and improving appearance for people with plaque psoriasis.
Operating room nurses describe critical trauma management challenges and teamwork dynamics in a qualitative review
Nurses share how trauma care shapes their daily work and personal lives
Fifteen experienced trauma nurses shared their lived experiences managing critical multiple injuries in a tertiary Hunan hospital. Their nar…
Fifteen experienced nurses describe the professional challenges, teamwork dynamics, and stress they face while managing critical trauma case…
FDA Approves Tremfya (guselkumab) for Ulcerative Colitis and Crohn's Disease
FDA approves Tremfya for ulcerative colitis and Crohn's disease.
The FDA approved Tremfya (guselkumab) for adults with moderately to severely active ulcerative colitis and Crohn's disease. The approval exp…
The FDA approved Tremfya (guselkumab) for adults with moderate to severe ulcerative colitis or Crohn's disease. It is the first drug of its …
Early preterm birth linked to lower atopic dermatitis risk in large meta-analysis
Preterm birth linked to lower allergy risk in children
A meta-analysis of observational studies involving over 5 million children found that early preterm birth was associated with a reduced risk…
Babies born early may have lower odds of developing eczema and hay fever, a large analysis finds.
High-certainty evidence suggests weight-loss interventions improve psoriasis severity and quality of life in adults
Weight loss linked to better psoriasis severity and quality of life
This systematic review and meta-analysis evaluated weight-loss interventions versus usual care or lower-intensity interventions in adults wi…
A review of 1,145 adults with psoriasis found weight-loss interventions improved skin severity and quality of life more than usual care.
Icotrokinra 200 mg daily achieves PASI 75 in 73% of patients at Week 16 versus 11% with placebo in moderate-to-severe plaque psoriasis
Oral icotrokinra shows strong results for moderate-to-severe plaque psoriasis
This systematic review and meta-analysis evaluates icotrokinra for moderate-to-severe plaque psoriasis in 1951 patients. The pooled analysis…
A new analysis finds oral icotrokinra helps clear skin faster than placebo in patients with moderate-to-severe plaque psoriasis.
Switching between adalimumab and biosimilar adalimumab-atto shows similar pharmacokinetics in plaque psoriasis
Switching between adalimumab and its biosimilar is safe and similar
This phase 3 RCT in 425 adults with moderate-to-severe plaque psoriasis found that multiple switches between adalimumab RP and biosimilar ad…
A new trial shows that switching between adalimumab and its biosimilar adalimumab-atto is safe and produces similar drug levels in the blood…
Quantitative PDA improves understanding and confidence versus qualitative PDA in dysplastic nevus screening
Quantitative tool improves understanding of dysplastic nevus risk
This randomized A/B testing study enrolled 600 US adults to compare Quantitative PDA against Qualitative PDA for dysplastic nevus screening.…
A new tool that shows numbers about mole risk helped adults understand their dysplastic nevus risk better than a descriptive tool, but did n…
ALK fusion Spitz neoplasms show distinct morphologic patterns and genomic correlates in meta-analysis
ALK fusion Spitz tumors: new patterns linked to behavior
This retrospective cohort study with meta-analysis of 144 patients with ALK fusion Spitz neoplasms describes morphologic patterns and genomi…
Spitz tumors with ALK fusions show distinct shapes and gene partners that may predict which ones turn aggressive.